Royal Bank of Canada Reaffirms "Outperform" Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN - Get Free Report)'s stock had its "outperform" rating restated by analysts at Royal Bank of Canada in a report issued on Friday, Marketbeat Ratings reports. They currently have a GBX 1,500 ($18.83) target price on the stock. Royal Bank of Canada's price target suggests a potential upside of 55.31% from the stock's previous close.

SN has been the subject of several other reports. JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,300 ($16.32) price objective on shares of Smith & Nephew in a research note on Wednesday. Barclays reiterated an "equal weight" rating and set a GBX 1,150 ($14.44) price objective on shares of Smith & Nephew in a research note on Friday, February 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 1,362.50 ($17.10).

Smith & Nephew Price Performance

Shares of SN stock traded down GBX 10.20 ($0.13) during mid-day trading on Friday, hitting GBX 965.80 ($12.12). 2,832,535 shares of the stock were exchanged, compared to its average volume of 343,671. The company has a quick ratio of 0.84, a current ratio of 1.77 and a debt-to-equity ratio of 59.11. Smith & Nephew has a 52-week low of GBX 887 ($11.13) and a 52-week high of GBX 1,316.75 ($16.53). The firm has a fifty day moving average of GBX 1,073.14 and a 200 day moving average of GBX 1,038.36. The company has a market cap of £8.44 billion, a PE ratio of 4,024.17, a price-to-earnings-growth ratio of 0.52 and a beta of 0.51.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.